Medically reviewed on August 8, 2017.
Applies to the following strengths: 62.5 mcg (0.0625 mg)/inh
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance
1 inhalation (62.5 mcg) orally once a day
Maximum dose: 1 inhalation every 24 hours
Use: Treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: No studies have been performed.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Administer at the same time every day.
-For oral inhalation only.
-The manufacturer product information should be consulted for instructions for use.
-This drug should not be used to relieve acute symptoms of COPD, extra doses should not be used for that purpose.
-Treat acute symptoms with an inhaled short acting beta2-agonist.
-Patients should seek medical attention immediately if their COPD symptoms get worse, if they need more inhalations than usual of their rescue inhaler, if they develop signs and symptoms of narrow-angle glaucoma and/or urinary retention.
-Patients should not stop therapy with this drug without physician/provider guidance since symptoms may recur after discontinuation.
-Discontinue this drug if paradoxical bronchospasm occurs.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about umeclidinium
- Umeclidinium Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 12 Reviews
- Drug class: anticholinergic bronchodilators
Other brands: Incruse Ellipta